Tags

Type your tag names separated by a space and hit enter

Family history of hematopoietic malignancy and risk of lymphoma.
J Natl Cancer Inst 2005; 97(19):1466-74JNCI

Abstract

BACKGROUND

A family history of hematopoietic malignancy is associated with an increased risk of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL), although the magnitude of the relative risk is unclear. We estimated the association between familial hematopoietic cancer and risk of lymphoma using validated, registry-based family data, and we also investigated whether associations between some environmental exposures and risk of lymphoma vary between individuals with and without such a family history.

METHODS

In a population-based case-control study of malignant lymphoma, 1506 case patients and 1229 control subjects were linked to the Swedish Multi-Generation Register and then to the Swedish Cancer Register to ascertain history of cancer in first-degree relatives of patients with malignant lymphoma. Multiple logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations with the risk of lymphoma.

RESULTS

A history of hematopoietic malignancy in any first-degree relative was associated with an increased risk of all NHL (OR = 1.8, 95% CI = 1.2 to 2.5), common B-cell NHL subtypes, and HL. Relative risks were generally stronger in association with sibling hematopoietic cancer (OR for all NHL = 3.2, 95% CI = 1.3 to 7.6) than with parental hematopoietic cancer (OR = 1.6, 95% CI = 1.1 to 2.3). A family history of NHL or chronic lymphocytic leukemia (CLL) was associated with an increased risk of several NHL subtypes and HL, whereas familial multiple myeloma was associated with a higher risk of follicular lymphoma. There was no statistically significant heterogeneity in NHL risk associations with environmental factors between individuals with and without familial hematopoietic malignancy.

CONCLUSIONS

The increased risk of NHL and HL among individuals with a family history of hematopoietic malignancy was approximately twofold for both lymphoma types. There was no evidence that etiologic associations varied between familial NHL and nonfamilial NHL.

Authors+Show Affiliations

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. ellen.chang@meb.ki.seNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

16204696

Citation

Chang, Ellen T., et al. "Family History of Hematopoietic Malignancy and Risk of Lymphoma." Journal of the National Cancer Institute, vol. 97, no. 19, 2005, pp. 1466-74.
Chang ET, Smedby KE, Hjalgrim H, et al. Family history of hematopoietic malignancy and risk of lymphoma. J Natl Cancer Inst. 2005;97(19):1466-74.
Chang, E. T., Smedby, K. E., Hjalgrim, H., Porwit-MacDonald, A., Roos, G., Glimelius, B., & Adami, H. O. (2005). Family history of hematopoietic malignancy and risk of lymphoma. Journal of the National Cancer Institute, 97(19), pp. 1466-74.
Chang ET, et al. Family History of Hematopoietic Malignancy and Risk of Lymphoma. J Natl Cancer Inst. 2005 Oct 5;97(19):1466-74. PubMed PMID: 16204696.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Family history of hematopoietic malignancy and risk of lymphoma. AU - Chang,Ellen T, AU - Smedby,Karin Ekström, AU - Hjalgrim,Henrik, AU - Porwit-MacDonald,Anna, AU - Roos,Göran, AU - Glimelius,Bengt, AU - Adami,Hans-Olov, PY - 2005/10/6/pubmed PY - 2005/10/15/medline PY - 2005/10/6/entrez SP - 1466 EP - 74 JF - Journal of the National Cancer Institute JO - J. Natl. Cancer Inst. VL - 97 IS - 19 N2 - BACKGROUND: A family history of hematopoietic malignancy is associated with an increased risk of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL), although the magnitude of the relative risk is unclear. We estimated the association between familial hematopoietic cancer and risk of lymphoma using validated, registry-based family data, and we also investigated whether associations between some environmental exposures and risk of lymphoma vary between individuals with and without such a family history. METHODS: In a population-based case-control study of malignant lymphoma, 1506 case patients and 1229 control subjects were linked to the Swedish Multi-Generation Register and then to the Swedish Cancer Register to ascertain history of cancer in first-degree relatives of patients with malignant lymphoma. Multiple logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations with the risk of lymphoma. RESULTS: A history of hematopoietic malignancy in any first-degree relative was associated with an increased risk of all NHL (OR = 1.8, 95% CI = 1.2 to 2.5), common B-cell NHL subtypes, and HL. Relative risks were generally stronger in association with sibling hematopoietic cancer (OR for all NHL = 3.2, 95% CI = 1.3 to 7.6) than with parental hematopoietic cancer (OR = 1.6, 95% CI = 1.1 to 2.3). A family history of NHL or chronic lymphocytic leukemia (CLL) was associated with an increased risk of several NHL subtypes and HL, whereas familial multiple myeloma was associated with a higher risk of follicular lymphoma. There was no statistically significant heterogeneity in NHL risk associations with environmental factors between individuals with and without familial hematopoietic malignancy. CONCLUSIONS: The increased risk of NHL and HL among individuals with a family history of hematopoietic malignancy was approximately twofold for both lymphoma types. There was no evidence that etiologic associations varied between familial NHL and nonfamilial NHL. SN - 1460-2105 UR - https://www.unboundmedicine.com/medline/citation/16204696/Family_history_of_hematopoietic_malignancy_and_risk_of_lymphoma_ L2 - https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/dji293 DB - PRIME DP - Unbound Medicine ER -